AC Immune weighs an IPO; Novartis plays catch-up in PD-1;

@FierceBiotech: FDA asks experts to weigh in on PCSK9 drugs' market reach for Amgen, Regeneron/Sanofi. Report | Follow @FierceBiotech

@JohnCFierce: If I set up a biotech, treated 4 patients with depression with ketamine and then touted the results, would people buy my stock? $SAGE | Follow @JohnCFierce

@DamianFierce: Excellent feature about ClickHole. And an excellent feature on ClickHole | Follow @DamianFierce

> AC Immune, awaiting word on whether partner Roche ($RHHBY) will move its Alzheimer's disease treatment into Phase III, is considering an IPO or outright sale, CEO Andrea Pfeifer says. More

> Despite trailing the likes of Merck ($MRK) and Bristol-Myers Squibb ($BMY) in the field of checkpoint inhibitors for cancer, Novartis believes it can catch up in a hurry thanks to a slew of acquisitions and licensing deals. News

> Canada's DalCor Pharmaceuticals is developing the Roche-abandoned heart drug dalcetrapib, betting it can succeed where its predecessor failed by homing in on patients with particular genetic mutations. Item

Medical Device News

@FierceMedDev: ICYMI from @StacyALawrence: Intarcia readies for FDA in 2016, reports detailed Ph III data for once-yearly diabetes implant. Report | Follow @FierceMedDev

@VarunSaxena2: ICYMI yesterday: Medtronic, BD to collaborate on diabetes infusion set featuring enhanced insulin delivery. Story | Follow @VarunSaxena2

> Medtronic launches bariatric surgery tool to enable more consistent procedures. Story

> Outset Medical rounds up $91M to make dialysis options more attractive. News

Pharma News

@FiercePharma: ICYMI yesterday: GSK's Advair dogged again as Mylan launches first bioequivalent copy in U.K. Article | Follow @FiercePharma

@EricPFierce: Mylan recalls more injected cancer drugs it made for Pfizer at its Agila plants in India. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: Could an $18.9B Shire bid convince Actelion to ditch its independence? More | Follow @CarlyHFierce

> No red flags in Januvia heart study means a big win for Merck. Story

> U.S. poised to spend $50B on just 10 'breakthrough' meds in 10 years. Report

> Pfizer scientist warned execs about Zoloft and birth defects, lawyers say. Article

Drug Delivery News

> Research group seeks to promote crystals as drug delivery, development tools. More

> Implanted device releases drugs to help determine cancer-killing course of action. Item

> Sebacia raises $8M, nears FDA submission of laser-activated microparticles for acne. News

> Braeburn's once-rejected implant to treat opioid abuse shown comparable to pills in pivotal trial. Story

> India's Cipla gets first FDA approval of oral pellet to treat HIV/AIDS in infants. Report

Pharma Manufacturing News

> Serious manufacturing issues tied to fungal contamination in NIH facility. News

> Mylan picks 3M to manufacture its generic Advair inhaler for U.K. market. Item

> Cardinal Health targets hospital sales with $1.1B bid for Harvard Drug Group. More

> Mylan expands recall of cancer meds made for Pfizer. Report

> AstraZeneca's manufacturing gets another boost with $125M Africa plant. Story

Pharma Asia News

> India's Sun says slow and steady on Ranbaxy plants, FDA on Wockhardt at odds with management. Item

> Complaints trickle in about higher drug prices in China after cap removal. Report

> China's 3SBio returns to market and pulls in $710.7M in HK IPO. More

> GSK, Sanofi hauled up by India's competition watchdog on vaccine tenders. Story

> Australia's Proteomics claims first predictive diabetic kidney disease diagnostic test. Article

Suggested Articles

Q32 Bio raised $60 million to push its lead antibody through the clinic and bolster its pipeline and the technology behind it.

Sanofi is teaming up with Merck while AstraZeneca taps Arcus as the future of cancer work is very much made together.

The action follows the FDA’s decision to reject a filing for approval of the JAK1 inhibitor in rheumatoid arthritis due to toxicity concerns.